ValiRx - ValiSeek Clinical Development Update
VAL
Tue, 12 Dec 2017, 07:30am GMT
ValiRx accelerates the development of treatments in cancer and women’s health to improve patient lives. We provide the scientific, financial and commercial framework to enable the rapid translation of innovative science into clinical development.
Industry: Health Care
Contact: +44 (0)2476 796496
Barling Way
https://www.valirx.com/
Dr Suzy Dilly, CEO of ValiSeek provides a positive update on the clinical progress of VAL401, the anti-cancer compound. The Company has released positive formal data pertaining to disease impact. The results demonstrate that the VAL401 treatment has a statistically significant improvement in Overall Survival for patients with non-small cell lung cancer compared to those receiving no treatment.